Baclofen decreases acid and non-acid post-prandial gastro-oesophageal reflux measured by combined multichannel intraluminal impedance and pH.
about
Acid and non-acid reflux in patients with persistent symptoms despite acid suppressive therapy: a multicentre study using combined ambulatory impedance-pH monitoringDiagnosis and treatment of patients with nonacid gastroesophageal reflux-induced chronic cough.Refractory chronic cough due to gastroesophageal reflux: Definition, mechanism and management.Management of the patient with incomplete response to PPI therapy.Gastro-oesophageal reflux monitoring: review and consensus report on detection and definitions of acid, non-acid, and gas refluxWeakly acidic reflux in patients with chronic unexplained cough during 24 hour pressure, pH, and impedance monitoringTreatment of GORD: Three decades of progress and disappointmentsAcid-based parameters on pH-impedance testing predict symptom improvement with medical management better than impedance parameters.Gastroesophageal reflux disease: From pathophysiology to treatmentArbaclofen placarbil decreases reflux with good tolerability in patients with gastroesophageal reflux disease (am j gastroenterol 2010;105:1266-1275)Dose-dependent effects of lesogaberan on reflux measures in patients with refractory gastroesophageal reflux disease: a randomized, placebo-controlled study.Effects of (2R)-(3-amino-2-fluoropropyl)sulphinic acid (AFPSiA) on transient lower oesophageal sphincter relaxation in dogs and mechanism of hypothermic effects in mice.Does reflux monitoring with multichannel intraluminal impedance change clinical decision making?Review article: the pathophysiology of gastro-oesophageal reflux disease - oesophageal manifestations.Alginate controls heartburn in patients with erosive and nonerosive reflux diseasePharmacological targets in gastro-oesophageal reflux disease.Review article: modern technology in the diagnosis of gastro-oesophageal reflux disease--Bilitec, intraluminal impedance and Bravo capsule pH monitoring.Non-acid gastroesophageal reflux: documenting its relationship to symptoms using multichannel intraluminal impedance (MII).The role of GABA(A) receptors in the control of transient lower oesophageal sphincter relaxations in the dogRecent developments in gastrointestinal motility.Utilising multichannel intraluminal impedance for diagnosing GERD: a review.Therapeutic efficacy of baclofen in refractory gastroesophageal reflux-induced chronic coughCurrent Diagnosis and Management of Suspected Reflux Symptoms Refractory to Proton Pump Inhibitor TherapyHigh-resolution manometry and impedance-pH/manometry: valuable tools in clinical and investigational esophagology.Effect of delta9-tetrahydrocannabinol, a cannabinoid receptor agonist, on the triggering of transient lower oesophageal sphincter relaxations in dogs and humansMultichannel intraluminal impedance and pH monitoring in gastroesophageal reflux disease.Non-acid reflux: detection by multichannel intraluminal impedance and pH, clinical significance and management.Emerging drugs for gastroesophageal reflux disease.Esophageal impedance monitoring for gastroesophageal reflux.Barrett's esophagus: proton pump inhibitors and chemoprevention I.Gastroesophageal reflux disease--from reflux episodes to mucosal inflammation.Therapeutic options for refractory gastroesophageal reflux disease.Novel therapeutics for gastro-esophageal reflux symptoms.NERD: an umbrella term including heterogeneous subpopulations.Current pharmacological management of gastroesophageal reflux disease.Refractory gastroesophageal reflux disease.The effects of baclofen for the treatment of gastroesophageal reflux disease: a meta-analysis of randomized controlled trialsAmbulatory reflux monitoring for diagnosis of gastro-esophageal reflux disease: Update of the Porto consensus and recommendations from an international consensus group.The selective metabotropic glutamate receptor 5 antagonist mavoglurant (AFQ056) reduces the incidence of reflux episodes in dogs and patients with moderate to severe gastroesophageal reflux disease.Current treatment options for esophageal diseases.
P2860
Q24679917-C436393D-887E-4A60-B68A-A34A8D620113Q26772194-B2A24BA2-6073-4158-A9A2-6F6FFEC37E97Q26785656-F59923A0-50E3-4BB2-80EA-8207B9E21D83Q27025882-C403AE5E-C3D5-4769-A641-C6E6C700F556Q33203720-BF556BCC-57B0-43ED-86D3-64671C4722B5Q33212653-73CA6300-41FA-42AD-9E8A-38205245EBCFQ33695362-94AA5DBC-D58F-4251-BD68-C7677972E8AAQ33924407-3E95B625-E441-4009-AA4A-7CC989145727Q34063683-441BA78E-4D9A-412D-8000-65A0AD6A7F41Q34298312-98F6CD33-3A87-466A-A906-36F845BCA331Q34895516-7BAEB801-2754-4F07-8708-8E05BED0F296Q35049112-8B798DDC-17E4-49A4-8CB1-919741134861Q35800679-570018EB-BB8C-4F46-8BF6-10D326AB89FEQ35939790-331E1055-FA6C-45D8-8A53-5EF6AE99644EQ36215537-E32E9BB1-72B8-46D8-B6E9-E53788961D6FQ36346427-9BB9912D-6834-42A6-A9E5-5987033E3DE7Q36398674-D90D2198-969D-469B-BF8E-2A24C5C8453BQ36429253-64207A7C-F5FB-4244-A61F-B57043263D60Q36510017-952062C7-64A3-4ADF-8C86-5D5CA2098F5AQ36510664-57EE1EE1-CBC8-4949-9527-EAC5A1E86016Q36793949-97DFF84D-F13D-4416-B147-D391791DF380Q37034055-C0B05AA9-E015-4C3C-8A51-ADFE8272E510Q37190537-831D839C-06D1-4A5F-A37A-57C1E40CE659Q37221211-B6F9FA1D-DA4F-4501-B022-95E18BB02534Q37230841-5FC83075-3307-4276-9C1E-3BC4B15C7816Q37345839-06EE4BC3-1C3C-423E-8E52-486B7D43FAE4Q37384688-FF44DFB5-5B09-41B6-9681-1DC5D62DBD40Q37570546-9280706B-A5AF-44D4-8357-C5C1B3FC926AQ37829303-91CDEEC5-F13B-4F19-BDED-4FCCA970CFE0Q37939281-521F8F3C-A33D-4FE3-8E60-5BA6362B05A9Q37959240-15AF7D02-956E-47F8-9DF3-E387058C0C19Q38001073-E708FBF4-FCED-4FB0-ADEE-BF208AE2DCC7Q38057369-3FDB416F-110B-4EA1-A725-509E438CCAAAQ38092939-76A6D95E-E9F3-474A-AC5C-C59351C3C300Q38123482-CC671668-4B20-4D5C-BEE2-EF6C7C538822Q38255997-2D34428E-8913-4C64-8CA7-1A03BF249B7BQ38267393-C33AC9CA-7A74-4A0B-8E14-8A169EB13D5AQ38859145-5DE93ED2-C906-44DE-AD78-BFE6008BF78AQ38880408-535E76B1-37B2-4006-A241-C5A4A689504CQ38890205-97AC4DAE-8473-4107-99E0-74EE5DE1D932
P2860
Baclofen decreases acid and non-acid post-prandial gastro-oesophageal reflux measured by combined multichannel intraluminal impedance and pH.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Baclofen decreases acid and no ...... intraluminal impedance and pH.
@en
Baclofen decreases acid and no ...... intraluminal impedance and pH.
@nl
type
label
Baclofen decreases acid and no ...... intraluminal impedance and pH.
@en
Baclofen decreases acid and no ...... intraluminal impedance and pH.
@nl
prefLabel
Baclofen decreases acid and no ...... intraluminal impedance and pH.
@en
Baclofen decreases acid and no ...... intraluminal impedance and pH.
@nl
P2093
P1476
Baclofen decreases acid and no ...... intraluminal impedance and pH.
@en
P2093
P2860
P304
P356
10.1046/J.1365-2036.2003.01394.X
P407
P50
P577
2003-01-01T00:00:00Z